Skip to main content

Advertisement

SpringerLink
Log in

Venetoclax-based combination therapy in R/R DLBCL patients with failure of CAR-T therapy

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

There are few effective therapeutic options available for R/R DLBCL patients who have undergone CAR-T therapy. We retrospectively assessed 10 R/R DLBCL patients with complete clinical records who received venetoclax-based combination therapy following CAR-T therapy failed in our center between July 2020 and December 2021. After receiving CAR-T therapy, they all relapsed within a few months. As salvage regimens, they were all given venetoclax-based combination therapy. The objective response rate (ORR) was 80 percent, and the complete response rate was 30 percent. At the time of the analysis, 7 patients were still living. Our research has demonstrated that venetoclax-based combination treatment for R/R DLBCL patients who failed CAR-T therapy has a high effectiveness and manageable toxicity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

Data availability

The datasets analyzed during the current study are available from the corresponding author on reasonable request.

References

  1. Gisselbrecht C, Van Den Neste E (2018) How I manage patients with relapsed/refractory diffuse large B cell lymphoma. Br J Haematol 182(5):633–643

    Article  PubMed  PubMed Central  Google Scholar 

  2. Sarkozy C, Sehn LH (2018) Management of relapsed/refractory DLBCL. Best Pract Res Clin Haematol 31(3):209–216

    Article  PubMed  Google Scholar 

  3. Abramson JS (2020) Anti-CD19 CAR T-Cell Therapy for B-cell non-Hodgkin lymphoma. Transfus Med Rev 34(1):29–33

    Article  PubMed  Google Scholar 

  4. Kapoor I, Bodo J, Hill BT, Hsi ED, Almasan A (2020) Targeting BCL-2 in B-cell malignancies and overcoming therapeutic resistance. Cell Death Dis 11(11):941

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Davids MS, Roberts AW, Seymour JF, Pagel JM, Kahl BS, Wierda WG et al (2017) Phase I first-in-human study of venetoclax in patients ewwith relapsed or refractory non-Hodgkin lymphoma. J Clin Oncol 35(8):826–833

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Franck Morschhauser PF (2021) A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma. Blood 137(5):600–609

    Article  PubMed  PubMed Central  Google Scholar 

  7. O’Steen S, Green DJ, Gopal AK, Orozco JJ, Kenoyer AL, Lin Y et al (2017) Venetoclax synergizes with radiotherapy for treatment of B-cell lymphomas. Cancer Res 77(14):3885–3893

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Weidong Han CT, Zhang Yajing (2020) Optimized tandem CD19 CD20 CAR-engineered T cells in refractory relapsed B cell lymphoma. Blood. 136(14):1632–44

    PubMed  PubMed Central  Google Scholar 

Download references

Funding

This study was supported by Translational Research Grant of NCRCH (No. 2020ZKMB02) and Suzhou science and technology development project (No.SYS2019039).

Author information

Authors and Affiliations

  1. National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China

    Ying Zhu, Sicheng Ai, Mengya Cong, Mao Jin, Xiao Ma & Haiwen Huang

  2. College of Art and Science, New York University, New York City, NY, USA

    Sicheng Ai

Authors
  1. Ying Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sicheng Ai
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mengya Cong
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mao Jin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Xiao Ma
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Haiwen Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

The work reported in the paper has been performed by the authors, unless clearly specified in the text. HH designed the research; YZ analyzed the data. MC and MJ performed the statistical analysis. SA critically assessed the manuscript; XM revised the manuscript and approved the final version, and all authors read and approved the final manuscript.

Corresponding author

Correspondence to Haiwen Huang.

Ethics declarations

Ethics approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Consent to participate

Informed consent was obtained from all individual participants included in the study.

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhu, Y., Ai, S., Cong, M. et al. Venetoclax-based combination therapy in R/R DLBCL patients with failure of CAR-T therapy. Ann Hematol 102, 597–601 (2023). https://doi.org/10.1007/s00277-023-05088-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-023-05088-7

Keywords

Search

Navigation